The Patent Finder

Usher III Initiative, Inc.

10 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2032
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 4, 2026
    The maintenance fee for Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (US 10,307,422) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
  • 1 fee due Jan 14, 2027
    The maintenance fee for Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome (US 9,079,909) comes due Jan 14, 2027. Unpaid by Jul 14, 2027, it lapses early.
  • 1 fee due Jul 5, 2027
    The maintenance fee for Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (US 9,227,976) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
  • 1 fee due Aug 16, 2027
    The maintenance fee for Pyrazolopyridazines and methods for treating retinal degenerative diseases and hearing loss associated with usher syndrome (US 9,260,381) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,079,909Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,260,381Pyrazolopyridazines and methods for treating retinal degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,549,910Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,925,187Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 10,307,422Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 8,765,762Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,227,976Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,371,332Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 9,783,545Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
In force
 · USPTO record
In forceUSPTO record
US 12,544,373Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited